Partial Clinical Hold Encountered Immediately After Large-Scale Technology Export

The U.S. Food and Drug Administration (FDA) has abruptly imposed a Partial Clinical Hold on BHV-7000 (generic name: Opakalim), a next-generation epilepsy treatment candidate from Biohaven. This measure restricts only the recruitment of new patients, while allowing the treatment of more than 600 patients already registered and receiving medication to continue normally. This regulatory measure, in particular, has heightened market tension by occurring just weeks after SK Biopharmaceuticals agreed to secure global rights for a total of $795 million, including an upfront payment of $350 million.

Issues with Preclinical Rodent Metabolomics Toxicity Signatures and Safety Verification

The clinical hold was triggered by the observation of a specific metabolite, formed during the degradation of the drug in vivo, in nonclinical rodent studies. Regulatory authorities have requested additional data to verify whether this metabolite poses a significant toxic risk to humans. Biohaven and SK Biopharmaceuticals stated that they had already shared this data during the due diligence process and believe it is likely a species-specific phenomenon limited to rodents; they plan to submit additional safety data within weeks.

Mechanism of Selective Potassium Channel Openers and Expected Synergy with XCOPRI

BHV-7000 is an innovative drug pipeline (with First-in-class potential) that selectively activates voltage-gated potassium ion channels (Kv7.2/7.3 Potassium Channels), directly inhibiting excessive excitation of brain nerve cells. To overcome the limitations of ezogabine (brand name Potiga), a first-generation potassium channel opener that was withdrawn from the market due to central nervous system depressant effects and side effects such as skin and retinal discoloration, target selectivity was maximized. SK Biopharm aims to consolidate its dominance in the central nervous system (CNS) market by cultivating BHV-7000 as a follow-up blockbuster, following Cenobamate (brand name Xcopri), which generates over 400 billion KRW in annual sales through its direct sales network in the United States.

Concerns Over Phase 3 Timeline Delays and Impact on Competitive Landscape

For the RISE3 trial, a pivotal Phase 3 study for patients with focal onset seizures, patient recruitment is already complete, and the schedule for announcing topline efficacy data within this year is expected to proceed as planned. However, for the RISE2 trial, which requires additional patient enrollment, a delay in the clinical timeline is inevitable until the FDA lifts the hold. This is a sensitive variable that could disadvantage the company in the development race against Xenon Pharmaceuticals, whose Azetukalner (XEN1101) is progressing smoothly through late-stage Phase 3 trials based on the same Kv7 mechanism.